23
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Amino Acid Region 1000–1008 of Factor V Is a Dynamic Regulator for the Emergence of Procoagulant Activity*

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background: Factor V is activated to factor Va to interact with factor Xa.

          Results: Elimination of nine amino acids from the B domain results in binding of unactivated factor V to factor Xa.

          Conclusion: Amino acids 1000–1008 of factor V prevent unwanted prothrombinase assembly.

          Significance: A short peptide sequence from the B region is a regulatory domain for the generation of factor Va procoagulant activity.

          Abstract

          Single chain factor V (fV) circulates as an M r 330,000 quiescent pro-cofactor. Removal of the B domain and generation of factor Va (fVa) are vital for procoagulant activity. We investigated the role of the basic amino acid region 1000–1008 within the B domain of fV by constructing a recombinant mutant fV molecule with all activation cleavage sites (Arg 709/Arg 1018/Arg 1545) mutated to glutamine (fV Q3), a mutant fV molecule with region 1000–1008 deleted (fV ΔB9), and a mutant fV molecule containing the same deletion with activation cleavage sites changed to glutamine (fV ΔB9/Q3). The recombinant molecules along with wild type fV (fV WT) were transiently expressed in COS-7L cells, purified, and assessed for their ability to bind factor Xa (fXa) prior to and following incubation with thrombin. The data showed that fV Q3 was severely impaired in its interaction with fXa before and after incubation with thrombin. In contrast, K D (app) values for fV ΔB9 (0.9 n m), fVa ΔB9 (0.4 n m), and fV ΔB9/Q3 (0.7 n m) were similar to the affinity of fVa WT for fXa (0.3 n m). Two-stage clotting assays revealed that although fV Q3 was deficient in its clotting activity, fV ΔB9/Q3 had clotting activity comparable with fVa WT. The k cat value of prothrombinase assembled with fV ΔB9/Q3 was minimally affected, whereas the K m value of the reaction was increased 57-fold compared with the K m value obtained with prothrombinase assembled with fVa WT. These findings strongly suggest that amino acid region 1000–1008 of fV is a regulatory sequence protecting the organisms from spontaneous binding to fXa and unnecessary prothrombinase complex formation, which in turn results in catastrophic physiological consequences.

          Related collections

          Most cited references52

          • Record: found
          • Abstract: not found
          • Article: not found

          Factor V: a combination of Dr Jekyll and Mr Hyde.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The contribution of bovine Factor V and Factor Va to the activity of prothrombinase.

            The rates of prothrombin activation under initial conditions of invariant concentrations of prothrombin and Factor Xa were studied in the presence of various combinations of Ca2+, homogeneous bovine Factor V, Factor Va, phosphatidylcholine-phosphatidylserine vesicles, and activated bovine platelets. Reactions were monitored continuously through the enhanced fluorescence accompanying the interaction of newly formed thrombin with dansylarginine-N-(3-ethyl-1,5-pentanediyl) amide. The complete prothrombinase (Factor Xa, Ca2+, phospholipid, and Factor Va) behaved as a "typical" enzyme and catalyzed the activation of prothrombin with an apparent Vmax of 2100 mol of thrombin/min/mol of Factor Va or Factor Xa, whichever was the rate-limiting component. Regardless of whether the enzymatic complex was composed of Factor Xa, Ca2+, and plasma Factor Va plus phospholipid vesicles, or activated platelets in the place of the latter components, similar specific activity values were observed. The combination of Factor Va, Ca2+, and phospholipid enhanced the rate of the Factor Xa-catalyzed activation of prothrombin by a factor of 278,000. Factor Va itself when added to Factor Xa, Ca2+, and phospholipid, enhanced the rate of prothrombin activation by a factor of 13,000. Unactivated Factor V appears to possess 0.27% of the procoagulant activity of thrombin-activated Factor Va. From the kinetics of prothrombinase activity, an interaction between Factor Xa and both Factor V and Factor Va was observed, with apparent 1:1 stoichiometries and dissociation constants of 7.3 x 10(-10) M for Factor Va and 2.7 x 10(-9) M for Factor V. The present data, combined with data on the equilibrium binding of prothrombinase components to phospholipid, indicate that the model prothrombinase described in this paper consists of a phospholipid-bound, stoichiometric complex of Factor Va and Factor Xa, with bound Factor Va serving as the "binding site" for Factor Xa, in concert with its proposed role in platelets.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The role of phospholipids and factor Va in the prothrombinase complex.

              The kinetic parameters of the conversion of bovine prothrombin into thrombin by activated bovine blood clotting factor X (Xa) have been determined in the absence and presence of Ca2+, activated bovine factor V (Va) and phospholipid (dioleoylphosphatidylcholine/dioleoylphosphatidylserine, 1:1; mol/mol). In the absence of accessory components, the Km for prothrombin is 131 microM, which is well above its concentration in bovine plasma of about 1.5 microM. The Vmax of thrombin formation is 0.61 mol min-1 mol of Xa-1 under these conditions. In the presence of 7.5 microM phospholipid, the Km drops to 0.058 microM and the Vmax slightly increases to 2.25 mol min-1 mol of Xa. For the complete prothrombinase complex (Xa, Va, Ca2+, and 7.5 microM phospholipid), a Km for prothrombin of 0.21 microM and a Vmax of 1919 mol min-1 mol of Xa-1 is found. The Vmax of thrombin formation slightly increases when more phospholipid is present in our experiments and there is a considerable increase of the Km for prothrombin at higher phospholipid concentrations. Preliminary calculations show that the prothrombin density at the phospholipid surface at the Km is independent of the phospholipid concentration. This indicates that the Km measured in the presence of phospholipid has to be regarded as an apparent Km and the local prothrombin concentration determines the kinetics of activation. Prothrombin activation by prothrombinase complexes of different compositions was followed by gel electrophoresis in the presence of sodium dodecyl sulfate. Both in the absence and presence of phospholipid but without factor Va, prethrombin 2 is the main product formed during the initial stages of steady state prothrombin activation. In the presence of factor Va, thrombin is the main end product and minute amounts of prethrombin 2 are formed. This shift in the reaction pathway of prothrombin activation caused by factor Va will contribute to the observed increase of the Vmax measured in the presence of factor Va.
                Bookmark

                Author and article information

                Journal
                J Biol Chem
                J. Biol. Chem
                jbc
                jbc
                JBC
                The Journal of Biological Chemistry
                American Society for Biochemistry and Molecular Biology (9650 Rockville Pike, Bethesda, MD 20814, U.S.A. )
                0021-9258
                1083-351X
                27 December 2013
                31 October 2013
                31 October 2013
                : 288
                : 52
                : 37026-37038
                Affiliations
                From the []Department of Chemistry, Cleveland State University, Cleveland, Ohio 44115,
                the [§ ]Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195,
                the []Center for Gene Regulation in Health and Disease, Cleveland State University, Cleveland, Ohio 44115, and
                the []Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio 44195
                Author notes
                [2 ] To whom all correspondence should be addressed: Cleveland State University, Department of Chemistry, 2351 Euclid Avenue, Science and Research Center SR370, Cleveland OH 44115. Tel.: 216-687-2460; Fax: 216-687-9298; E-mail: m.kalafatis@ 123456csuohio.edu .
                [1]

                Supported in part by Doctoral Dissertation Research Expense Award and Fellowship Program (DDREAFP) at Cleveland State University (to JRW).

                Article
                M113.462374
                10.1074/jbc.M113.462374
                3873559
                24178294
                98e982c9-c8f7-424b-bd40-9266a5e8538f
                © 2013 by The American Society for Biochemistry and Molecular Biology, Inc.

                Author's Choice—Final version full access.

                Creative Commons Attribution Unported License applies to Author Choice Articles

                History
                : 15 February 2013
                : 25 October 2013
                Funding
                Funded by: National Institutes of Health
                Award ID: R01 HL-73343
                Categories
                Protein Structure and Folding

                Biochemistry
                thrombin,factor xa,coagulation factors,phospholipid vesicle,protein chemistry,prothrombin,factor v,factor va,prothrombinase

                Comments

                Comment on this article